Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
Nirupama Putcha,1 Ayca Ozol-Godfrey,2 Shahin Sanjar,2 Sanjay Sharma2 1Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USACorrespondence: Nirupama PutchaDivision of Pulmonary and Critic...
Main Authors: | Putcha N, Ozol-Godfrey A, Sanjar S, Sharma S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-04-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/impact-of-comorbidity-prevalence-and-cardiovascular-disease-status-on--peer-reviewed-fulltext-article-COPD |
Similar Items
-
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
by: Ohar JA, et al.
Published: (2020-05-01) -
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
by: Ohar JA, et al.
Published: (2021-05-01) -
Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
by: Tashkin DP, et al.
Published: (2021-04-01) -
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
by: Hanania NA, et al.
Published: (2021-03-01) -
Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
by: Ohar J, et al.
Published: (2018-12-01)